[China, Suzhou] -- On July 14, 2023, GeneQuantum, a leading pioneer committed to innovative bioconjugation technology, and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, signed a collaboration agreement. GeneQuantum granted non-exclusive licensing of its proprietary  conjugation technology to InxMed, supporting the development of the next generation of targeted conjugate ADC drugs.

According to the agreement, GeneQuantum will provide InxMed with its independently developed, globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform. This will support InxMed in developing innovative ADC drugs. The agreement was signed following the successful concept validation results of the candidate drugs developed by both parties. After the agreement is signed, GeneQuantum will receive an upfront payment and will be eligible for milestone payments related to specific research and development progress and sales. They will also receive royalties based on the net commercial sales of the ADC products.

After the agreement is signed, InxMed will have the right to use GeneQuantum’s enzymatic site-specific conjugation technology on the candidate molecules mentioned above. InxMed will be responsible for the research, development, manufacturing, and commercialization of the ADC candidate molecules. GeneQuantum will provide the necessary raw materials and technical support for drug development. This collaboration will enable both parties to leverage their respective technological advantages and resources, accelerate the research and development process of innovative ADC drugs, and provide more treatment options for patients worldwide.

Dr. Gang Qin, the founder and chairman of GeneQuantum, stated, "We are pleased to collaborate with InxMed. Founded by globally renowned clinical and translational medicine expert, Dr. Zaiqi Wang, InxMed possesses profound insights and extensive experience in target selection and innovative drug development. We are honored that InxMed has chosen GeneQuantum's next-generation site-specific glycan conjugation technology (iGDC) after a comprehensive evaluation of global ADC conjugation technologies. Over the past decade, GeneQuantum has built a strong foundation in proprietary conjugation technology and integrated commercialization solutions. With iGDC as a leading example of the new generation of site-specific conjugation technology, GeneQuantum has gained significant industry attention and recognition. We believe that in combination with GeneQuantum's intelligent continuous conjugation process technology, iGDC will empower a diverse range of monoclonal and bispecific antibodies with abundant target options, transforming them into leading biopharmaceutical conjugate therapies, achieving safe and efficient therapeutic outcomes. We will continue to maintain an open mindset, sharing resources and advantages with the upstream and downstream sectors of the innovative drug industry chain, and jointly build an industry ecosystem. We will spare no effort to support InxMed in advancing its core products to the clinical stage as quickly as possible."

Dr. Zaiqi Wang, founder, chairman, and CEO of InxMed, stated, "We are pleased to collaborate with GeneQuantum in this partnership. InxMed has made significant breakthroughs in the field of tumor resistance and metastasis. Through various types of drugs, including ADC, InxMed aims to better address this vast unmet clinical need."

About GeneQuantum Healthcare

GeneQuantum is a global innovative biopharmaceutical company and one of the pioneers dedicated to the development of ADC drugs using enzyme-mediated site-specific conjugation technology. It has established a comprehensive technical system, iLDC® and iGDC®, which can provide end-to-end solutions for various conjugated drugs, from molecular design to commercial production. Based on this technology platform, GeneQuantum has successfully developed multiple clinically advanced innovative ADC products. ADC drugs empowered by GeneQuantum's conjugation technology have significant advantages in process quality and metabolic stability, with seamlessly integrated intelligent conjugation processes into antibody processes, resulting in a substantial reduction in overall commercial production costs. GeneQuantum is committed to empowering the development of various biopharmaceutical conjugated drugs worldwide and achieving collaborative partnerships and win-win cooperation in the field. For more information, please visit: www.genequantum.com.

About InxMed

InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and is committed to becoming a global leader in revolutionary cancer therapies.

InxMed has established translational medicine and clinical teams at Shanghai, Beijing, and Nanjing in China, and hubs in the United States, Canada and Australia. Through independent discovery research and development, product license-in, and collaborative research and development, InxMed has built a unique and synergistic global pipeline. Its first novel drug, IN10018, a FAK (Focal Adhesion Kinase) small molecule inhibitor, received Fast-track Designation from the U.S. Food and Drug Administration and Breakthrough Therapy Designation from the China National Medical Products Administration. The pivotal clinical trial supporting market approval is ongoing.